Development outcomes Sample Clauses

Development outcomes. The recent development outcomes concern the update of the swagger API file and the publication of the enabler as open source by following a BSD license.
Sample 1Sample 2
AutoNDA by SimpleDocs
Development outcomes. The work that has been done during INSPIRE5G+ project is: ● The definition and development of the external APIs ● Finalizing the implementation and proceeding to some tests ● Submitting a scientific paper to an international conference. ● Discussion with partners in order to create new use cases and collaborations
Sample 1
Development outcomes. The enabler consists of the Python libraries running in the background for receiving and analysing the monitoring data and the NodeJS / Node-RED GUIs for visualizing the collected statistics as well as the analysis results. The videos listed below will demonstrate how the dashboards look. Videos: ● Playlist (will be kept updated with new videos): xxxxx://xxx.xxxxxxx.xxx/playlist?list=PL8Qwr001wPnY4lsCBzuBv0h-xilmTfg8z ● RCA-Principal idea (September-2020): xxxxx://xxxxx.xx/0Hixis8QXo0 ● RCA Dashboard (Beta version- October 2020): xxxxx://xxxxx.xx/Ri4EU66qb4A ● RCA ITS (March 2021): xxxxx://xxxxx.xx/5eU2oSNIArU In addition, in the following table we provide details about the API exposed by RCA that enables the integration of RCA with other enablers. A set of high-level commands are exposed by RCA in the form of a REST API. Table 4 RCA-M API Method Resource Content-type Description GET /rca/getall Response: application/json To retrieve all the records (known incidents) stored in the historical database GET /rca/getone Response: application/json To retrieve a record (a known incident) stored in the historical database identified by its ID POST /rca/insertone Response: application/json Parameter: application/json To report a newly detected incident with all the related traces so that it could be inserted to the historical database GET /rca/logs Response: text/plain To retrieve all the logs of the tool GET /rca/status Response: application/json To retrieve the current status of the monitored system and how it looks similar (in percentage) to the known incidents GET /rca/help Response: application/json To retrieve the API documentation POST /rca/update Response: application/json Parameter: application/json To push an update regarding a record (a known incident) in the historical database POST /rca/deleteone Response: application/json Parameter: application/json To delete a record (a known incident) in the historical database POST /rca/deletemany Response: application/json Parameter: application/json To delete multiple records (known incidents) in the historical database
Sample 1
Development outcomes. We released a format of manifest which describe a class of Components and several examples to illustrate its use. We also developed services in the Liability-Aware Security Manager of T4.4 which use this manifest.
Sample 1
Development outcomes. Initial version of PoT was based on an initial proof of concept prototype used in conjunction with Quantum Key Distribution (QKD) technology referenced in the State of the art subsection to provide order verification, a.k.a. Ordered Proof of Transit (OPoT). The solution carries a dedicated protocol with specific cryptographic payload packet. This work allowed isolating the OPoT from QKD technology to increase its applicability in other areas where QKD systems are not available, and progress in the internal design of the enabler. The developments made in T4.1 have included: x The creation of a centralized mechanism for key generation and distribution͕ ͞WŽd ŽŶƚƌ as alternative to distributed QKD system to keep the order property and key material protection. This solution makes the oPoT compatible with quantum and classical cryptography. x Enrich interactions between the agents and the controller to increase the visibility and status of the verifications. The added information includes the node-by-node cryptographic material and calculations. x Include by default timestamp information, so it can be used in metrics generations (RTT, latency or hop-by-hop delays). x Support customized ports and protocols (UDP/TCP) by configuration so it can be adapted to different environments. x Improve metrics and log generations, so it can be used by Trust Manager in their calculations.
Sample 1
Development outcomes. CCT developments are based on the existing version. In previous versions (see the detailed description of the enabler), it was developed for Java software (developed in the context of FP7 OPTET) and for VNF using a TOSCA descriptor (developed in the context of 5G ENSURE). The next steps are to identify the new components to be evaluated, their trustworthiness properties and their associated metrics. The previous versions have implemented automatic evaluations but also manual evaluations (based on evidence coming from test results for example). This approach could be reused for evaluating a larger number of components. 7 OPerational Trustworthiness Enabling Technologies | OPTET Project | FP7 | CORDIS | European Commission (xxxxxx.xx) 8 The Opa Language: xxxx://xxxxxxx.xxx/
Sample 1
Development outcomes. An alpha version of the Trust Reputation Manager is currently being developed. The required entries for trust calculation have been identified for those enablers identified as trust aware in the initial set of Use Cases, taking into account different entries for different entities. In addition, we are defining the way enablers should publish data to the Integration Fabric (in particular to the Xxxxx service embedded into it) and how the TRM will subscribe to those events to retrieve the information. The infrastructure on top of which the test cases relying on this enabler are deployed, must support this Integration Fabric, in particular the Xxxxx, as well as the DLT on which the Smart Contracts being defined are going to be deployed. In that regard, the testbed in Murcia has already the necessary elements as the reference deployment for the enabler.
Sample 1
AutoNDA by SimpleDocs
Development outcomes. Regarding the development of this enabler, the initial architecture has been designed and developed to allow a Network Slice Manager to participate in the Blockchain system. Moreover, a work on smart contracts (the current Blockchain system is based on Ethereum) has been done to allow operations between the peers. In addition, a set of tests had been planned and designed in order to start getting a set of initial results. Currently we are finishing the tests to validate its main functionalities to manage E2E Network Slices (deploy them, terminate them and get their information). By the end of this current year, it is planned to have an initial demo integrating this enabler and the Component Certification Tool.
Sample 1
Development outcomes. Currently, the RAG model, and risk evaluation algorithms and the optimization algorithm for solving the counter-measure placement problem are now re-implemented in Python C++17 17 (name of the C++ standard approved in 2017) in order to improve their running time. This enables the algorithms to scale much better than the previous Python implementation. as well as the optimization algorithm for solving the counter-measure placement problem using the MIP solver CPLEX. The REST API is currently in development and relies on Flask (xxxxx://xxxxx.xxxxxxxxxxxxxxx.xxx) and a Python binding of the C++ code.
Sample 1

Related to Development outcomes

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Area 10.4. The Development Area shall encompass all Deposits to be produced.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Curriculum Development This includes the analysis and coordination of textual materials; constant review of current literature in the field, some of which are selected for the college library collection, the preparation of selective, descriptive materials such as outlines and syllabi; conferring with other faculty and administration on curricular problems; and, the attendance and participation in inter and intra-college conferences and advisory committees.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

Time is Money Join Law Insider Premium to draft better contracts faster.